skip to content


IP Group and CIC create Microbiotica

19 December 2016 07:39

IP Group has announced the creation of Microbiotica Ltd, a newly formed spin-out company from the Wellcome Trust Sanger Institute, established to commercialise the Sanger Institute's ground-breaking research into the role of the human microbiome in disease. IP Group is co-leading this investment with Cambridge Innovation Capital, a Cambridge-based investor in technology and healthcare companies in which IP Group is a shareholder, with a £4m contribution from each party to provide total initial funding of £8m.

This reflects IP Group and CIC's ongoing partnership under which they share information on investment and co-investment opportunities in the Cambridge Cluster. Recognition of the importance to human health of the trillions of bacteria that reside in the human intestine - known as the gut microbiome - has created major opportunities in the diagnosis and treatment of a wide range of diseases including cancer, infection and metabolic, neurological and autoimmune disorders.

The Sanger Institute team, led by Dr Trevor Lawley, has been at the forefront of this research, having built one of the world's most extensive collections of cultured human gut bacteria with associated genome analysis, along with humanised models for the development of therapeutics based on live bacteria. Microbiotica has been granted unique access to these resources and will use the funding from IP Group and CIC to establish labs within the Wellcome Genome Campus at Hinxton, Cambridge, and to progress multiple live bacteriotherapy programmes into development.

Story provided by

Related Company: IPO

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.